Jaehyuk Choi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8320025/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol. Journal of Investigative Dermatology, 2022, 142, 493-496.e7.	0.7	3
2	Partial remission of advanced untreated Sézary syndrome after COVID-19. JAAD Case Reports, 2022, 21, 165-168.	0.8	2
3	Acceleration of Skin Involvement May Predict Disease Progression in Early-Stage Mycosis Fungoides: A Retrospective Cohort Study. Journal of the American Academy of Dermatology, 2022, , .	1.2	0
4	YIA22-008: Identification of Biomarkers That Predict Responses to Immunotherapy in Merkel Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, YIA22-008.	4.9	0
5	Gut dysbiosis in cutaneous Tâ€cell lymphoma is characterized by shifts in relative abundances of specific bacterial taxa and decreased diversity in more advanced disease. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1552-1563.	2.4	6
6	Classification of human chronic inflammatory skin disease based on single-cell immune profiling. Science Immunology, 2022, 7, eabl9165.	11.9	53
7	The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion. Journal of Investigative Dermatology, 2022, 142, 3253-3261.e4.	0.7	0
8	Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides. JAAD Case Reports, 2021, 7, 87-90.	0.8	2
9	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. Blood Advances, 2021, 5, 649-661.	5.2	26
10	Differences in Merkel cell carcinoma survival by site of primary presentation. Journal of the American Academy of Dermatology, 2021, , .	1.2	1
11	Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity. Blood, 2021, 138, 1225-1236.	1.4	49
12	Cutting Edge: Steroid Responsiveness in Foxp3+ Regulatory T Cells Determines Steroid Sensitivity during Allergic Airway Inflammation in Mice. Journal of Immunology, 2021, 207, 765-770.	0.8	7
13	Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. Blood, 2021, 138, 2435-2440.	1.4	10
14	ZEB1 promotes pathogenic Th1 and Th17 cell differentiation in multiple sclerosis. Cell Reports, 2021, 36, 109602.	6.4	22
15	BACH2 is a putative T cell lymphoma tumor suppressor that may play a role in product-derived CAR-T cell lymphomas. Blood, 2021, , .	1.4	4
16	Scarring alopecia developing after mogamulizumab-associated rash. European Journal of Dermatology, 2021, 31, 841-843.	0.6	2
17	Single-Cell Profiling Reveals Divergent, Globally Patterned Immune Responses in Murine Skin Inflammation. IScience, 2020, 23, 101582.	4.1	30
18	Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. Journal of the American Academy of Dermatology, 2020, 83, 197-199.	1.2	80

Јаенуик Сној

#	Article	IF	CITATIONS
19	Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Nature Communications, 2020, 11, 1806.	12.8	62
20	Celastrol-loaded PEG- <i>b</i> -PPS nanocarriers as an anti-inflammatory treatment for atherosclerosis. Biomaterials Science, 2019, 7, 657-668.	5.4	66
21	EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1311-1320.	1.2	249
22	The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. Frontiers in Pharmacology, 2019, 10, 200.	3.5	82
23	Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Reports, 2019, 5, 1018-1026.	0.8	24
24	Progression of undiagnosed cutaneous lymphoma after anti–tumor necrosis factor-alpha therapy. Journal of the American Academy of Dermatology, 2018, 78, 1068-1076.	1.2	46
25	Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival. Clinical Cancer Research, 2018, 24, 963-971.	7.0	57
26	Are there multiple cells of origin of Merkel cell carcinoma?. Oncogene, 2018, 37, 1409-1416.	5.9	84
27	Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure. Journal of Investigative Dermatology, 2018, 138, 384-393.	0.7	44
28	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. Journal of Investigative Dermatology, 2018, 138, 2365-2376.	0.7	59
29	Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). , 2018, 6, 39.		329
30	A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nature Communications, 2018, 9, 3196.	12.8	145
31	Are MicroRNAs Key to Developing Biomarkers for Cutaneous T-Cell Lymphoma?. Journal of Investigative Dermatology, 2018, 138, 1906-1908.	0.7	4
32	Hemophagocytic Lymphohistiocytosis in Cutaneous T-Cell Lymphoma. JAMA Dermatology, 2018, 154, 828.	4.1	21
33	Photopheresis: Advances and Use in Systemic Sclerosis. Current Rheumatology Reports, 2017, 19, 31.	4.7	11
34	LB959 Hemophagocytic lymphohistiocytosis in cytotoxic cutaneous T-cell lymphoma: DelayedÂdiagnosis of a life-threatening complication. Journal of Investigative Dermatology, 2017, 137, B5.	0.7	0
35	Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma. Cellular Immunology, 2017, 319, 28-34.	3.0	9
36	Promoting early detection of melanoma during the mammography experience. International Journal of Women's Dermatology, 2017, 3, 195-200.	2.0	6

Јаенуик Сној

#	Article	IF	CITATIONS
37	Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood, 2017, 130, 1430-1440.	1.4	131
38	CD8 + mycosis fungoides: A low-grade lymphoproliferative disorder. Journal of the American Academy of Dermatology, 2017, 77, 489-496.	1.2	31
39	FISH Panel for Leukemic CTCL. Journal of Investigative Dermatology, 2017, 137, 751-753.	0.7	11
40	Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. Journal of Investigative Dermatology, 2017, 137, 951-954.	0.7	61
41	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?. Oncotarget, 2017, 8, 100863-100898.	1.8	16
42	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget, 2016, 7, 3403-3415.	1.8	306
43	Secondary Cutaneous Diffuse Large B-cell Lymphoma has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-cell Lymphoma, Leg Type. Acta Dermato-Venereologica, 2016, 96, 245-250.	1.3	25
44	Advancements in unresectable melanoma: a multidisciplinary perspective. Melanoma Management, 2016, 3, 171-175.	0.5	0
45	Nonoverlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi. Journal of Investigative Dermatology, 2016, 136, 1858-1865.	0.7	27
46	071 Novel FISH probe panel for the detection of gene copy number alterations in CTCL. Journal of Investigative Dermatology, 2016, 136, S13.	0.7	1
47	IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro-Oncology, 2016, 18, 1402-1412.	1.2	126
48	Defining the polyposis/colorectal cancer phenotype associated with the Ashkenazi <i>GREM1</i> duplication: counselling and management recommendations. Genetical Research, 2016, 98, e5.	0.9	11
49	Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood, 2016, 127, 948-951.	1.4	52
50	Telomere Replication Stress Induced by POT1 Inactivation Accelerates Tumorigenesis. Cell Reports, 2016, 15, 2170-2184.	6.4	94
51	Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside. Current Treatment Options in Oncology, 2016, 17, 33.	3.0	51
52	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2170-2175.	7.1	102
53	Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. Journal of the American Academy of Dermatology, 2016, 74, 870-877.	1.2	36
54	A Discordant Cutaneous Eruption in a Neonatal Twin. JAMA Dermatology, 2016, 152, 463.	4.1	2

Јаенуик Сној

#	Article	IF	CITATIONS
55	Genomic landscape of cutaneous T cell lymphoma. Nature Genetics, 2015, 47, 1011-1019.	21.4	347
56	A primary melanoma and its asynchronous metastasis highlight the role of <i><scp>BRAF</scp></i> , <i><scp>CDKN2A</scp></i> , and <scp><i>TERT</i></scp> . Journal of Cutaneous Pathology, 2015, 42, 108-117.	1.3	12
57	Identification of <scp>PLX</scp> 4032â€resistance mechanisms and implications for novel <scp>RAF</scp> inhibitors. Pigment Cell and Melanoma Research, 2014, 27, 253-262.	3.3	44
58	Rapidly Enlarging Nodular Plaque on the Leg. JAMA Dermatology, 2014, 150, 1107.	4.1	5
59	Control of a <i>Salmonella</i> virulence operon by proline-charged tRNA ^{Pro} . Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3140-3145.	7.1	43
60	Activation of GILZ gene by photoactivated 8-methoxypsoralen: Potential role of immunoregulatory dendritic cells in extracorporeal photochemotherapy. Transfusion and Apheresis Science, 2014, 50, 379-387.	1.0	23
61	Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features. International Journal of Dermatology, 2011, 50, 1480-1485.	1.0	28
62	Carpal Tunnel Syndrome Associated with the Use of Aromatase Inhibitors in Breast Cancer. Clinical Breast Cancer, 2008, 8, 362-365.	2.4	24
63	Cutaneous T-cell Lymphoma. Hematology/Oncology Clinics of North America, 2008, 22, 979-996.	2.2	31
64	46 PHOSPHORYLATION OF SODIUM CHANNEL NAV1.8 BY P38 MAPK INCREASES CURRENT DENSITY IN DRG NEURONS. European Journal of Pain, 2007, 11, S19-S19.	2.8	0
65	Cutaneous T-cell lymphoma: Biologic targets for therapy. Current Hematologic Malignancy Reports, 2007, 2, 272-277.	2.3	2
66	Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. Yale Journal of Biology and Medicine, 2006, 79, 169-72.	0.2	4
67	Endothelial Cells Promote Human Immunodeficiency Virus Replication in Nondividing Memory T Cells via Nef-, Vpr-, and T-Cell Receptor-Dependent Activation of NFAT. Journal of Virology, 2005, 79, 11194-11204.	3.4	27
68	Human Endothelial Cells Enhance Human Immunodeficiency Virus Type 1 Replication in CD4+ T Cells in a Nef-Dependent Manner In Vitro and In Vivo. Journal of Virology, 2005, 79, 264-276.	3.4	27
69	T Lymphocyte–EndothelialCellInteractions. Annual Review of Immunology, 2004, 22, 683-709.	21.8	179
70	Inhibition of Phosphatidylinositol 3-Kinase Sensitizes Vascular Endothelial Cells to Cytokine-initiated Cathepsin-dependent Apoptosis. Journal of Biological Chemistry, 2003, 278, 21295-21306.	3.4	55